Regulatory
Sep 24, 2026 · 1 min read · 23,939 views
Updated: Ultragenyx's new gene therapy will cost $3.95M
M
Maya Chen
Editorial · Sep 24, 2026
FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 failure
← Previous
Post-Hoc Live: The China Biotech Debate goes to Washington
Next →
A federal AI experiment could transform chronic care - if doctors and patients want it
